Clinical Trial Update: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating AB248 alone or with pembrolizumab in adults with solid tumors, including non-small cell lung cancer, melanoma, head and neck squ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• AB248
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Asher Biotherapeutics, Inc. | Conditions: Solid Tumor, Non Small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING